Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 11/20 | 0.37 |
| ▸ | PPARA | Q07869 | 11/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12288693 | 0.83 | SLC6A2 (0.46) | SLC6A2SLC6A3SLC6A4PPARGPPARA | |
| SCHEMBL12290347 | 0.83 | SLC6A2 (0.44) | SLC6A2SLC6A3SLC6A4PPARGPPARA | |
| SCHEMBL2554529 | 0.79 | SLC6A2 (0.52) | SLC6A2SLC6A3SLC6A4PPARGPPARA | |
| SCHEMBL2558920 | 0.72 | SLC6A2 (0.57) | SLC6A2SLC6A3SLC6A4PPARGPPARA | |
| SCHEMBL2320829 | 0.72 | SLC6A2 (0.57) | SLC6A2SLC6A3SLC6A4PPARGPPARA | |
| SCHEMBL764989 | 0.71 | SLC6A2 (0.67) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL11224068 | 0.71 | IDO1 (0.48) | SLC6A2SLC6A3SLC6A4PPARGPPARA | |
| SCHEMBL2557131 | 0.70 | PPARA (0.48) | SLC6A2SLC6A3PPARGPPARA | |
| SCHEMBL11399686 | 0.69 | SLC6A2 (0.53) | SLC6A2SLC6A3SLC6A4PPARGPPARA | |
| SCHEMBL27536785 | 0.68 | SLC6A2 (0.47) | SLC6A2SLC6A3SLC6A4PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2555623-A1 | FLAVIN DERIVATIVES | BioRelix, Inc. (US) | 2013-02-13 | — | — | EP | disclosed |
| US-20130029980-A1 | FLAVIN DERIVATIVES | COISH PHILIP D G (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029980-A1 | FLAVIN DERIVATIVES | COISH PHILIP D G (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029980-A1 | FLAVIN DERIVATIVES | COISH PHILIP D G (US) | 2013-01-31 | — | — | US | disclosed |
| WO-2011126567-A1 | FLAVIN DERIVATIVES | BIORELIX, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011126567-A1 | FLAVIN DERIVATIVES | BIORELIX, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029980-A1 | FLAVIN DERIVATIVES | BLVRB, FLAD1, FDPS | SLC6A2 3041/4885SLC6A3 2847/4885SLC6A4 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.